… In this study, BRAF V600E mutation was associated with aggressive disease in small
papillary thyroid carcinoma ≤ 1.5 cm and papillary thyroid microcarcinoma ≤ 1 cm, defined by: …

… BRAF mutation in thyroid cancer occurs only in PTC and PTC-derived anaplastic … that tumors
with BRAF V600E mutation were almost twice as likely (RR = 1.79) as those with BRAF wild-…

… meta-analysis to evaluate the associations between the BRAF V600E mutation status and
aggressive clinicopathological features and poor prognostic factors in papillary thyroid cancer. …

… good survival despite the aggressive clinical presentation. BRAF mutation has also been …
However, the reported rates of BRAF mutation vary significantly between studies. Lee et al. […

… the aggressive tumor behavior of BRAF+ PTC. The question arises whether BRAF mutation
plays a role as a prognostic marker, and how we should deal with BRAF+ tumors. This issue …

… In the current study, 95 specimens of thyroid tumors were subjected to BRAF mutation
analysis. The clinicopathological findings of all the specimen is presented in Table-1. The median …

… In PTC, TERT promoter mutation was more frequent in BRAF mutated tumors [31], which is
… promoter mutations, five (83.3%) had a coexisting BRAF mutation. TP53, a tumor suppressor …

… correlate with BRAF V600E mutation status,16, 25 however, our data did not corroborate
this. Additionally, BRAF V600E mutation status was not found to be associated with aggressive …

… for BRAF V600E mutation. The presence of BRAF V600E mutation is not an aggressive …
lack of correlation between BRAF V600E mutation and either aggressive clinicopathological …

… thyroiditis and BRAF V600E mutation status in patients with papillary thyroid cancer (PTC)
and … Hashimoto's thyroiditis and BRAF V600E mutation status influence PTC aggressiveness. …